Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr.
Reddy's Laboratories announces DCGI approval to the single-shot Sputnik Light vaccine in India"
This is for your information.
| /s/ Vivek Mittal | |
| Vivek Mittal | |
| Global General Counsel and Compliance Officer |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com | USHA IYER ushaiyer@drreddys.com |
Laboratories announces DCGI approval to the single-shot Sputnik Light vaccine in India
Hyderabad, India, February 7, 2022 -
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr. Reddy's")
today announced that the Drugs Controller General of India (DCGI) has granted approval to the single-shot Sputnik Light vaccine
for restricted use in emergency situation in India.
Sputnik Light is a one-dose vaccine and the
same as the first component-recombinant human adenovirus serotype number 26 (rAd26)-of the two-dose Sputnik V vaccine.
Following its Phase III clinical trial of the single-shot Sputnik Light vaccine in India, Dr. Reddy's had submitted its application
for approval to the DCGI in December 2021, in addition to data from clinical trial in Russia.
The standalone Sputnik Light vaccine is the
latest vaccine to be approved by the DCGI as part of India's national inoculation effort against COVID-19. Sputnik Light
is the second COVID-19 vaccine to be made available in India by Dr. Reddy's, reaffirming the company's commitment to
explore every avenue in the fight against the pandemic.
Sputnik Light has been approved in over 30
countries around the world including Argentina, UAE, Philippines and Russia. Earlier this year, an independent comparative study
conducted by the Spallanzani Institute in Italy showed that Sputnik V demonstrates strong protection against the Omicron variant,
with over two times higher virus neutralising activity compared to the Pfizer vaccine1. The data supports the results
of the recent laboratory study by the Gamaleya Center demonstrating that Sputnik V induces robust neutralising antibody response
to the Omicron variant, further strengthened by Sputnik Light as a booster2.
In September 2020, Dr. Reddy's partnered
with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and distribute the vaccine in India. In
April 2021, the DCGI granted approval to the two-dose Sputnik V vaccine for restricted use in emergency situation in India.
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services including APIs,
custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across
the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on
to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency
exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration
issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services
to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus
(or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission,
including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report
on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.
Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals: https://www.medrxiv.org/content/10.1101/2022.01.15.22269335v1
2 Sputnik Light booster after Sputnik V vaccination
induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant: https://www.medrxiv.org/content/10.1101/2021.12.17.21267976v1